Mizuho analyst Graig Suvannavejh raised the firm’s price target on Harmony Biosciences (HRMY) to $39 from $36 and keeps an Outperform rating on the shares following the Q3 report. The firm cites the strong Wakix performance for the target increase.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences Holdings: Strong Q3 Performance and Growth Potential Justify Buy Rating
- Harmony Biosciences Reports Strong Q3 2025 Results
- Harmony Biosciences Q3 Earnings Call Highlights Robust Growth
- Promising Outlook for Harmony Biosciences: Buy Rating Affirmed Due to Strong Product Momentum and Pipeline Progress
- Harmony Biosciences price target raised to $32 from $31 at BofA